[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Showa Inan General Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":122},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,37,59,82,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":36},"100403635","effectiveness-of-serum-leucine-rich-alpha-2-glycoprotein-levels-on-ibd-100403635",false,"NCT04535882","Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD","Association Between Serum Leucine-rich Alpha-2 Glycoprotein Levels and Endoscopic Activity of Possible Ulcerative Colitis or Crohn's Disease Colitis","Inclusion Criteria:\n\n* Patients whom possible UC or Crohn disease was suspected\n\nExclusion Criteria:\n\n* other autoimmune diseases\n* acute or chronic renal failure\n* chronic heart diseases\n* liver cirrhosis\n* cancer\n* acute or chronic infections\n* ischemic colitis\n* infectious colitis","ALL",{"count":18,"type":19},300,"ESTIMATED","OBSERVATIONAL","We attempt to examine the association between serum leucine-rich alpha-2 glycoprotein (LRG) levels and endoscopic activity in patients with possible ulcerative colitis (UC) or Crohn's disease (CD) to determine whether LRG was a predicting marker for UC or CD.",[23],"LRG Levels","RECRUITING","2026-05-09",{"date":27,"type":28},"2026-05-13","ACTUAL",{"date":30,"type":28},"2020-10-01",{"date":32,"type":19},"2026-12-31",{"name":34,"class":35},"Showa Inan General Hospital","OTHER",1,{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":16,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":48,"conditions":49,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":36},"100544724","association-between-lrg-and-histologic-remission-in-ulcerative-colitis-100544724","NCT06372613","Association Between LRG and Histologic Remission in Ulcerative Colitis","What is the Level of Serum Leucine-rich α 2-glycoprotein (LRG) Which Predicts Histologic Remission in Patients With Ulcerative Colitis?","Inclusion Criteria:\n\n* active UC patients\n\nExclusion Criteria:\n\n* None","20 Years","90 Years",{"count":47,"type":19},100,"We attempt to clarify the serum leucine-rich α 2-glycoprotein (LRG) level which can predict histologic remission in ulcerative colitis patients in this study. Colonoscopy with histology will be performed when histologic remission is predicted, irrespective of symptoms or serum LRG values. Serum LRG levels are analyzed by an enzyme-linked immunosorbent assay.",[50],"Ulcerative Colitis in Histologic Remission","2026-04-21",{"date":53,"type":28},"2026-04-24",{"date":55,"type":28},"2024-02-25",{"date":57,"type":19},"2027-12-31",{"name":34,"class":35},{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":36},"100611673","efficacy-and-safety-of-etrasimod-in-elderly-patients-with-ulcerative-colitis-100611673","NCT07243639","Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colitis","A Prospective Study on the Efficacy and Safety of a Novel Oral Drug, Etrasimod, in Elderly Patients With Ulcerative Colitis","Inclusion Criteria:\n\n* Patients with active ulcerative colitis\n\nExclusion Criteria:\n\n* the presence of acute or chronic renal failure, chronic heart disease, pulmonary infection, liver cirrhosis, colorectal cancer, autoimmune disease, and infectious disease",{"count":67,"type":19},30,"INTERVENTIONAL",[70],"NA","Eligible patients will be identified in regular clinical practice. After providing thorough explanation and obtaining voluntary written informed consent, the clinical course, adverse events, endoscopic findings, and histopathological changes in biopsy specimens after Etrasimod administration will be prospectively collected and analyzed.",[73],"Ulcerative Colitis (Disorder)","2025-12-09",{"date":76,"type":28},"2025-12-11",{"date":78,"type":28},"2025-10-01",{"date":80,"type":19},"2026-09-30",{"name":34,"class":35},{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":68,"phases":92,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":103,"locationsCount":36},"100390801","the-beneficial-effect-of-tj-134-for-patients-with-symptomatic-pneumatosis-cystoides-intestinalis-100390801","NCT04368663","The Beneficial Effect of TJ-134 for Patients With Symptomatic Pneumatosis Cystoides Intestinalis","The Beneficial Effect of the Traditional Japanese Medicine, Keishi-ka-shakuyaku-daio-to（TJ-134）for Patients With Symptomatic Pneumatosis Cystoides","Inclusion Criteria:\n\n* typical findings of PCI on colonoscopy; Line or pebble like sessile cysts are distributed around the colon with normal overlying mucosa\n\nExclusion Criteria:\n\n* patients can not take Keishi-ka-shakuyaku-daio-to（TJ-134）","18 Years","100 Years",{"count":47,"type":19},[70],"The traditional Japanese medicine, Keishi-ka-shakuyaku-daio-to is administered to patients with symptomatic pneumatosis cystoides intestinalis (PCI) as compared with lactomin for 8 weeks.",[95],"Pneumatosis Cystoides Intestinalis",[95],"2025-05-14",{"date":99,"type":28},"2025-05-15",{"date":101,"type":28},"2020-05-01",{"date":32,"type":19},{"name":34,"class":35},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":4,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":44,"maxAge":45,"enrollmentInfo":111,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":116,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":36},"100254733","bleeding-rate-after-egd-and-colonoscopy-in-patients-who-continue-to-take-antithrombotic-agents-100254733","NCT02594813","Bleeding Rate After EGD and Colonoscopy in Patients Who Continue to Take Antithrombotic Agents","EGD","Inclusion Criteria:\n\n* Inclusion criteria is all patients who continue to take antithrombotic drugs and undergo EGD or colonoscopy\n\nExclusion Criteria:\n\n* Patients who take prophylactic clipping after biopsy or polypectomy American Society of Anesthesiologists physical status of class IV or V",{"count":112,"type":19},10000,"The bleeding rate of both EGD (including biopsy) and colonoscopy (including biopsy, cold or hot snare polypectomy, or EMR) in patients who continue to take various antithrombotic drugs is studied prospectively. The immediate or delayed bleeding that requires hemostatic clipping or other endoscopic treatments is defined as the bleeding. Immediate bleeding requiring hemostatic clipping is defined as spurting or oozing which continued for more than 30 seconds. Delayed bleeding is defined as bleeding that requires the endoscopic treatment within 2 weeks after endoscopy. Prophylactic clipping is not performed after taking biopsy and doing polypectomy. Additionally, investigators evaluate the rate of injured submucosal arteries of the excised specimen when the bleeding occurs.",[115],"Bleeding After GI Endoscopy",{"date":99,"type":28},{"date":118,"type":4},"2015-11",{"date":120,"type":19},"2026-12",{"name":34,"class":35},""]